网页

Monday, April 30, 2018

Governor Baker, Secretary Ure?a, Major General Keefe Meet with World War II Veteran Sidney Walton

Governor Baker, Secretary?Ure?a, Major General Keefe Meet with World War II Veteran Sidney Walton


Governor Baker meets with World War II Veteran Sidney Walton and his son Paul Walton as part of the “Go Sidney Go” National No Regrets Tour across the United States.

For more high-resolution photos, click?here.

BOSTON?–?Today, Governor Charlie Baker,?Secretary of the Department of Veterans’ Services Francisco Ure?a and Massachusetts National Guard Adjutant General Gary Keefe presented a citation to Sidney Walton for his years of distinguished service to the U.S. Army during World War II. Sidney was also presented with the Massachusetts Medal of Merit by the Massachusetts Army National Guard for his outstanding service to the United States Armed Forces.

As part of his?National No Regrets Tour, Sidney Walton is travelling across the country with his son, Paul Walton, to meet with governors from all 50 states before concluding with a visit to the White House on his 100th?birthday in February 2019.

Sidney’s one regret was missing an opportunity to meet with the last surviving Civil War veterans prior to joining the United States Army in 1941. The?National No Regrets Tour?gives people across the country a chance to meet with one of the last surviving WWII veterans. Last year, there were approximately 558,000 veterans still alive in the U.S. out of 16 million Americans who served in WWII.

MGM Springfield to Officially Open August 24, 2018

MGM Springfield to Officially Open August 24, 2018

$960 Million MGM Resorts International Property Marks Largest Private Investment in Western Massachusetts’ History?

SPRINGFIELD, MASS.?(April 26, 2018) – Expanding its presence on the East Coast, MGM Resorts International will open the doors to?MGM Springfield, New England’s first integrated luxury resort and entertainment destination, on?Friday, August 24, 2018.

“A testament to a decade of collaboration between the City of Springfield and MGM Resorts, MGM Springfield will pay tribute to the city’s legacy and celebrate its bright future, while introducing a stellar array of hospitality and entertainment experiences that will attract guests from New England and beyond,” said Michael Mathis, President of MGM Springfield. “We are incredibly proud to debut what we believe will become the region’s premier entertainment destination and play a role in an exciting renaissance for Springfield.”

Mayor Domenic J. Sarno states, “I look forward to working with MGM Springfield for many years to come. They’re a world-class company and an outstanding corporate citizen. I deeply appreciate their belief and investment in our Springfield. I wish them continued success as we create another ‘Springfield first!’”

MGM Springfield will commemorate the city’s rich history through the preservation and reimagination of its most storied buildings. Locals and tourists can experience venues such as the First Spiritualist Church, Springfield Armory and Chandler Union Hotel – where Presidents Polk and Buchanan both stayed – in an entirely new way.

MAYOR WALSH LAUNCHES PLANNING PROCESS TO END YOUTH HOMELESSNESS IN BOSTON

MAYOR WALSH LAUNCHES PLANNING PROCESS TO END YOUTH HOMELESSNESS IN BOSTON
?BOSTON -?Monday, April 30, 2018 - On Friday, Mayor Martin J. Walsh joined members of the City's Youth Action Board to launch?Rising to the Challenge: Ending Youth & Young Adult Homelessness in Boston, the City of Boston's community planning process centered around preventing and ending homelessness among unaccompanied youth and young adults. The Youth Action Board is the City's consumer advisory group of youth and young adults who have current or former experience with homelessness or housing instability.??

"Whether it's attendance and graduation rates, unemployment and the local economy, youth incarceration rates, or emergency room costs, the effects of youth and young adult homelessness are broad," said Mayor Walsh. "I'm proud that our city is taking the critical first steps in ending youth homelessness. Each of the Youth Action Board members -- and their peers -- have important stories to tell us, and will contribute so much to the creation of this plan. There is a role for all of us to play in ending youth and young adult homelessness in Boston, and I look forward to working with everyone who has came together to reach this goal."

Boston's Way Home,?the Walsh Administration's plan to end chronic and veteran homelessness, highlighted unaccompanied youth and young adults as a priority population and identified the need for a comprehensive plan to prevent and end youth and young adult homelessness in Boston.?Rising to the Challenge?gathered community partners to launch the 4-month process of developing the first draft of this comprehensive plan.

In February 2018,?the City selected Matthew Aronson?and his team of consultants to build on the City's work to end youth homelessness in Boston by researching and creating an action plan to support young individuals experiencing homelessness and put them on pathways towards stable housing. Aronson and his team facilitated Friday's event, which was held at the Bolling Building in Roxbury with more than 150 people in attendance, including youth and young adults and community partners from City, State, and nonprofit agencies.

At?Rising to the Challenge, Mr. Aronson's team presented data they compiled in an attempt to estimate the size and scale of unaccompanied youth and young adult homelessness in Boston. In Boston, just like in most cities across the country, many youth and young adults experiencing homelessness are not sleeping in shelters or on the streets but are "doubled up" or couch surfing from one unstable situation to another. For this reason, it is challenging to estimate the full number of youth experiencing homelessness. An important part of this strategic plan will be to gather additional data about this group.

Boston's annual Homeless Census shows that on a given night, 360 youth and young adults are either sleeping in Boston's shelters or on the street. The City's data also shows that the majority of these youth and young adults stay in shelter for a week or less.

In addition to gathering additional data on youth and young adult homelessness, the City's plan will require a new understanding of the current system's capacity; identifying the unmet needs of youth and young adults; and designing a plan to address gaps in Boston's emergency assistance system that will end youth homelessness. The plan will be tied to concrete investments in housing and services necessary to end youth homelessness.

The plan will outline how to find resources for youth and young adults to access better permanent connections, education and employment, and improve their health and well-being. Creation of the plan will involve disparate stakeholders from across Boston, including law enforcement and adult and juvenile justice; healthcare providers; educators; the State's child welfare system; landlords; school programs and private foundations.

Throughout the day, attendees broke into small groups to discuss the current state of youth and young adult homeless services and an ideal future system, as well as concrete steps to take for a successful planning process.

Youth and young adults are central in the planning process. The Boston Youth Action Board participates in all planning committees and and meets monthly with representatives from the?Department of Neighborhood Development.

Prior to the launch of the community planning process, Aronson and his team focused on assisting the City in applying for the U.S. Office of Housing and Urban Development's Youth Homelessness Demonstration Program, a grant that would provide an estimated $2-$3 million to the City of Boston to develop and implement its plan to end youth homelessness.

In January 2016, Mayor Walsh announced Boston had ended chronic veteran homelessness; to date, nearly 850 homeless veterans have been housed. In 2016, the City scaled up its efforts to end chronic homelessness; and since January of 2016, 425 chronically homeless individuals have been housed, representing more than 3,000 years of homelessness ended. ?

Sunday, April 29, 2018

麻州今年4人角逐州长 查理贝克金库厚实

麻州州长查理贝克 (Charlie Baker)。(档案照片,周菊子摄)
(Boston Orange 周菊子整理报导) 麻州的州级选举两年一度,今年(2018)还要改选州长。在共和党也出现挑战者,民主党还没初选,就已三减一的有人退出下,选情发展似乎格外有趣。
麻州共和党428日在屋斯特(Worcester)举行了党员大会,结果在位州长查理贝克(Charlie Baker)从大约2400名出席党代表那儿,取得69.8%的支持度。
民主党籍的麻州州长候选人Jay Gonzalez。(档案照片,周菊子摄)
查理贝克的唯一对手,Scott Lively,一名很边缘,几乎没请任何助选员,也没筹款的候选人,却得到27.7%的党代表支持,轻松跨过必须有15%党代表支持,才能在初选选票上列名的门槛。
这一结果意味着在94日初选前,有着全美最受欢迎州长之誉的查理贝克,必须先花时间争取共和党员的支持,再来面对民主党的挑战。
麻州共和党的党代表们经过两轮投票後,还支持麻州众议员Geoff Diehl,这麻州内支持川普声音的领导者,作为共和党对抗民主党伊莉莎白沃伦(Elizabeth Warren)的联邦参议员候选人。
民主党籍麻州州长候选人Robert Massie。(档案照片,周菊子摄)
不过,联邦参议员这席位,共和党今年也得办初选。另外两名争取到15%以上党代表支持的候选人,分别为来自Groton的前麻州政府官员Beth Lindstrom,以及来自温彻斯特(Winchester)的商人John Kingston
麻州保守共和党籍会会长Lou Daxland表示,Scott Lively的跨过初选门槛,说明了他们也有声音。
这些保守共和党员对贝克的拒绝支持川普总统,但支持堕胎,同性恋婚姻等自由派社会政策,以及和议会中民主党员关系良好,都很不满。
贝克会後对媒体表示,Scott Lively说的,或相信的很多事,都不是主流观点,在任何公众生活,或是在任生活中都无地可容的。那也是为什麽他很高兴在大会中,每10名党代表,就有7人支持他今秋代表他们。
倍投方案图片顿环球报指出,查理贝克拒绝回答诸如他是否会和Scott Lively辩论,会否在2020年的连任竞选时支持川普。
??????????? Scott Lively的竞选户口中只有23,000
??????????? Scott Lively最为人知的是他写的那些备受争议,关於同性恋者的文章,包括他宣称同性控制了德国纳粹党。他曾经在2014年以独立无党派身分参选,得票率不到1%。他似乎成了共和党右翼不满份子的鞭子。
麻州共和党在党代表大会上还支持了三名无同党竞争对手的候选人参选州级职位,包括州务卿候选人,和州长查理贝克都住在Swampscott Anthony M. Amore,麻州稽核长候选人,住在Concord镇的Helen Brady,以及麻州财政长候选人,住在Lakeville的现任麻州众议员Keiko M. Orrall
麻州民主党预定於62日举行党代表大会,将在曾在派区克(Deval Patrick)州长任内担任麻州预算长的Jay Gonzalez,以及环保活跃份子,曾在1994年获民主党提名参选副州长的Robert Massie两人中做一抉择。
麻州民主党中,原本有至少3人参选州长。2017年五月正式宣布参选的前牛顿市市长塞提华伦(Setti Warren),却在大前天的426日宣布退选。
塞提华伦在一篇很长的公开信中表示,选战打了一年後,他的竞选帐户只剩下51,644元,和麻州现任州长查理贝克的有790万元,差距太大,更何况查理贝克还有着全美最受欢迎州长的光环,支持率高逾70%
今年一月卸任牛顿市长一职後,现年47岁的塞提华伦在刚被麻州大学倍投方案图片顿分校买下,即将关门的Mount Ida 学院任教,年薪7万元。他为参选州长,聘有10名员工,还有许多义工。
截至415日,民主党的Jay Gonzalez,竞选帐户还有 $127,418.27Robert Massie则有$20,831.25。共和党籍的查理贝克则有$7,893,135.25Scott Lively$22,952.23

美国运输部长赵小兰访中国 国务院总理李克强晤见

中国国务院总理李克强在美国运输部部长赵小兰赴中国出席中美交通论坛期间,晤见了她和运输政策副助理部长
杰龙(Joel Szabat, 左二)等人。
(Boston Orange 周菊子整理报导)美国运输部部长赵小兰(Elaine Chao)访问中国,出席中美交通论坛期间,426日晤见了中国国务院总理李克强,谈及中美贸易摩擦问题。李克强指两国应可经由对话化解冲突,中方的谈判大门一直开着。
新华社,彭博新闻,南华早报等多家中英文媒体都报导了这一晤谈。
赵小兰这次访问中国是为出席中美交通论坛第九次会议,会见李克强时的随行团员包括运输政策助理部长杰龙(Joel Szabat)
426日这天,赵小兰还会见了中国外交部长王毅。拜会照片及新闻稿,随後也出现在中国外交部官网上,简述称双方就中美关系及共同关心的其他问题交换了意见。
美国路透社在报导中指出,美国财政部长Steven Mnuchin已预定(五月)
率团访华,舒缓两国之间的贸易紧张情势。
早前美国总统川普威胁要向包括手机、电脑,消费性等中国产品课徵1000亿元关税,中国也报复性的展开向美国出口到中国产品课徵关税500亿元行动。
在新华社的报导中,李克强表示,贸易冲突,没有赢家,不但影响世界经济复苏,也影响全球工业链。
?即将随同美国财政部长到中国北京访问的川普高级经济顾问Larry Kudlow在上周四表示,他希望和中国的晤谈会有进展,但要解决美国的抱怨,过程恐怕会很长。
川普早前也说美国很有机会和中国就贸易达成协议。
新华社引述李克强的话说,他希望两国能够管控歧异。
川普曾批评中国提高对美国公司的贸易障碍,包括对诸如汽车等行业徵收高额进口税。
李克强重申习近平有关中国向世界开放贸易的保证,表示中国正坚定不移的进一步向外界开放,最近才宣布要废除国内汽车企业的外资拥有权上限,并删减进口税。
中国公司,包括百度,都在积极推动无人驾驶车辆,和美国由谷歌(google)母公司阿尔法贝特(Alphabet)支持的Waymo,以及特斯拉等竞争愈趋强烈。

安丰贵位台商讲解美国就业机会平等法


【波城台湾商会专题讲座? 安丰贵主讲就业平等】

驻倍投方案图片顿台北经文处处长徐佑典()、副处长陈铭俊(右二)
侨教中心主任欧宏伟(左一)与新英格兰大倍投方案图片顿台湾商会
会长欧阳露(左一)及主讲人安丰贵(左二)合影。
新英格兰大倍投方案图片顿台湾商会於428日在倍投方案图片顿侨教中心举办「就业机会平等」专题讲座,邀请美国联邦就业机会平等委员会主任安丰贵担任主讲人,向20余位与会人士介绍成功企业有关就业机会平等的理念,并以实际案例说明企业主及职员相关法令规定,包括性别平权、职场平权、机会平等等议题,获得一致肯定与好评。

驻倍投方案图片顿台北经文处处长徐佑典致词感谢商会举办此一深具意义
及知识性的专题讲座。
主办单位负责人欧阳露会长表示,这是一个难得的机会,可以让会员获得有关就业机会平等的法令规定与知识,可以保障自己本身的权益,也可以让雇主避免因疏忽违反相关规定;活动主讲人安丰贵以英文发表专题演讲,介绍相关就业法令、知识,并举实例加以说明,让大家更清楚在就业前、职场中,甚至离职後的相关规定,同时他也欢迎大家有任何问题,都可以和就业机会平等委员会联系。

美国联邦就业机会平等委员会主任安丰贵介绍成功企业有关
就业机会平等的理念与实务。
驻倍投方案图片顿台北经济文化办事处处长徐佑典、副处长陈铭俊和倍投方案图片顿侨教中心主任欧宏伟都应邀出席,向与会人士问候致意。徐佑典致词时,特别感谢商会举办此一深具意义及知识性的专题讲座;欧宏伟也表示,他与主讲人安丰贵是多年前的旧识,他的父母亲来自台湾,以他优秀的双语能力,定能为台湾商会会员及本地侨胞乡亲提供质量俱优的服务。(图与文:倍投方案图片顿侨教中心提供)





Friday, April 27, 2018

张锋创办的新公司Beam疗法 总融资额已逾8500万元


(Boston Orange)倍投方案图片顿商业期刊(BBJ)(27)日发表独家报导,指刚当选为美国艺术科学院院士,又是基因剪辑先驱的MIT教授张锋,在两家着名创投公司支持下,和人合夥,悄悄在剑桥市又创办了一家公司,Beam Therapeutics
根据PitchBook资讯,今年二月,这家Beam疗法公司在A轮融资中,从ARCH创投合夥人及F-Prime资本筹得1300万元。一名熟悉此事者还透露,Beam疗法迄今拿到的融资总额已达8500万元。
Beam疗法公司的发言人拒绝回应。
张锋在哈佛大学和麻省理工学院合作创办的博德研究院(Broad Institute)中占有重要分量,是研发 CRISPR/Cas9DNA剪辑工具的主要人物。他的新公司是基因剪辑领域,也是科学家们用方法来改变人类DNA,以永久治癒疾病做法的新成员,
张锋已经是已上市公司Editas医药的创办人兼科学顾问。剑桥市目前有3家上市公司,应用CRISPR/Cas9来找新药。
张锋最近在剑桥市还和人合办了另一家基因剪辑公司,Arbor生物科技,想要研发改变RNA的药,把DNA中指令转成身体内蛋白质的分子。
熟悉Beam早期营运的人表示,该公司采用了另一种名叫基地剪辑(base editing)”,涉及改变个人DNA却不切割双螺旋的方法。
最近的研究显示,这种方法可更精确的更改DNA,在治疗"点突变(point mutations)”造成的疾病时,特别有效。
不过尽管基因剪辑公司近几年来很火红,这一科技在美国仍待进行临床试验。Editas和另一家坐落在剑桥的初创公司CRISPR疗法都说将於今年向FDA申请做人体试验。
至於张锋所发现,和CRISPR/Cas9 有关的技术,目前仍涉及备受瞩目,上诉中的法律讼案。加州大学称生物学家Jennifer DoudnaMax Planck研究院的Emmanuelle Charpentier,更早发现这方法。

哈佛华人生命科学协会订 5/5办年会

Harvard Chinese Life Science?Annual Symposium 2018
May 5th, 2018
Folkman Auditorium, Enders Building, Boston Children’s Hospital320 Longwood Ave, Boston, MA 02115
Organizing Committee
Harvard Medical School - Chinese Scientists & Scholars Association(HMS-CSSA)
Song Yang, Qiong Ye, Linchang Huang, Wenqing Cai, Wei Li, Bin Li, Xiaoqing Wang, Shuxi Qiao, Hong Yue, Jingyu Peng, Yue Zhang, Xianrui Yang, Miao Liu, Chan Cao, Yiming Zhou, An Xiao, Yang Zhang, Yue Huang, Lijie Xing, Mohui Wei, Shengqing Gu, Tao Wang, Xiaofeng Li, Zhengnian Li, Hui Liu, Jiye Liu, Junlin Guo, Pingping Mao, Su Wang, Shuang Zhou, Jinmiao Chen, Songwei Duan, Yanan Qi
Organizing Committee Advisors
Jianzhu Chen, Professor, Massachusetts Institute of Technology
Chuan He, Professor, University of Chicago
Xi He, Professor, Boston Children’s Hospital, Harvard Medical School
Zhigang He, Professor, Boston Children’s Hospital, Harvard Medical School
Frank Hu, Professor, Harvard T.H.Chan School of Public Health?
Xiaole Shirley Liu, Professor, Dana-Farber Cancer Institute / Harvard T.H.Chan School of Public Health?
Hongbo Luo, Associate Professor, Harvard Medical School
William Pu, Professor, Boston Children’s Hospital, Harvard Medical School
Yang Shi, Professor, Boston Children’s Hospital, Harvard Medical School
Jiping Wang, Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School
Hao Wu, Professor, Boston Children’s Hospital, Harvard Medical School
Yingzi Yang, Professor, Harvard School of Dental Medicine
Junying Yuan, Professor, Harvard Medical School
Yi Zhang, Professor, Boston Children’s Hospital, Harvard Medical School
Jean Zhao, Professor, Dana-Farber Cancer Institute, Harvard Medical School


Invited Speakers

George Daley, MD, PhDHarvard Medical School, Boston Children’s Hospital
Dr. George Q. Daley seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008). As a graduate student working with Nobel Laureate Dr. David Baltimore, Dr. Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.
Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was one of twelve individuals in the school’s history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital (94-95) and is currently a staff physician in Hematology/Oncology at the Children's Hospital and the Dana Farber Cancer Institute, and a member of the Hematology Division of the Brigham and Women’s Hospital in Boston. He has been elected the National Academy of Medicine(NAM), the American Society for Clinical Investigation, the American Association of Physicians, and the American Pediatric Societies, and is a fellow of the American Academy of Arts and Sciences (AAAS) and the American Association for the Advancement of Science.
??
Xiang-Dong Fu, PhDDepartment of Cellular and Molecular Medicine, University of California, San Diego
Dr. Fu’s laboratory is interested in molecular and cell biology of RNA metabolism and regulation in higher eukaryotic cells. Current research interests in the Fu lab include the regulation of alternative splicing, functional RNA elements in mammalian genomes, transcription/splicing coupling, nuclear architecture, and cellular reprogramming. Dr. Fu was a major contributor for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to Fellow of American Association for the Advancement of Science (2010).
Dr. Fu is a Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).

Rudolf Jaenisch, PhD
Founding Member of Whitehead InstituteDepartment of Biology, MIT
Dr. Jaenisch lab’s expertise is in epigenetics, reprogramming and stem cells. Dr. Jaenisch began his research career as a pioneer making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, nuclear cloning, and, most recently, the nature of stem cells. In addition, using mice as a model and a technique called “altered nuclear transfer,” Dr. Jaenisch has demonstrated that it is possible to procure embryonic stem cells without harming a viable embryo. More recently he has demonstrated that somatic cells can be reprogrammed in vitro to pluripotent ES-like cells and that these cells are suitable to correct both genetic and induced defects in mice by transplantation therapy. Using this technique for turning skin cells into stem cells, the lab has been able to cure mice of sickle cell anemia -- the first direct proof that these easily obtained cells can reverse an inherited disease.
Dr. Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He has been granted numerous awards from organizations across the world. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases. Dr. Jaenisch received his doctorate in medicine from the University of Munich in 1967. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.

Xi He, PhDBoston Children’s Hospital, Harvard Medical School
Dr. He’s laboratory seeks to understand the molecular basis of cell-to-cell communication, and how this communication regulates embryonic and neural development in vertebrates. Dr. He is also interested in learning how defective regulation of cell communication causes human cancers and diseases. In particular, Dr. He is investigating signaling mechanisms employed by secreted growth factors of the Wnt family, which play critical roles in establishing the anterior-posterior axis of the embryo and underlie the formation of head versus trunk regions during early embryogenesis. Wnt signaling pathways are also pivotal in the development of human cancers--as several key Wnt signaling components are encoded by human oncogenes or tumor suppressor genes--and in the pathogenesis of many human diseases, such as osteoporosis and degenerative disorders. Dr. He aims to identify molecular components of Wnt signaling pathways and the mechanisms by which Wnt pathways are activated and governed during embryonic development and human tumorigenesis.?
Dr. He received his bachelor’s degree in engineering at Huazhong University of Science and Technology (HUST), Wuhan, China, and Ph.D. in Dr. Michael G. Rosenfeld’s lab at University of California, San Diego (UCSD). After his postdoctoral training with Dr. Harold Varmus at National Cancer Institute (NCI), Dr. He became an Assistant Professor at Boston Children’s Hospital in 1997. He was promoted to professor in 2007. Dr. He was a Pew Scholar, a Klingenstein Fellow, a W. M. Keck Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. Dr. He received the Young Investigator Award from the Society of Chinese Bioscientists in America (SCBA) in 2004, and holds a Chang Jiang Guest Professorship and 1000 Talent Plan (B) Professorship at HUST. Dr. He is an elected Fellow of American Association for the Advancement of Science and an American Cancer Society Research Professor. He has served on numerous review and advisory boards in academia and the biopharmaceutical industry in the USA, Canada, EU, UK and China.

William Pu, MDBoston Children's Hospital, Harvard Medical School
The Pu lab is interested in the regulation of gene expression and cell lineage specification in heart development, disease, and regeneration using various technologies including genetically engineered mice, conditional gene inactivation, genome-wide chromatin occupancy analysis, and RNA expression profiling. The major goals of Dr. Pu's research include: 1. To understand the transcriptional network regulating heart development and disease; 2. To understand cell lineage specification in heart development and regeneration; 3. To understand genetic contributions to congenital heart disease.
Dr. Pu received an MD from Harvard Medical School. He completed his internship, residence, and pediatric cardiology training at Boston Children’s Hospital. Dr. Pu has been an independent PI since 2004 and has an established track record of innovation in cardiovascular biology. Dr. Pu has 19 successful postdoctoral fellow “alumni”. Among those, 12 remain in academic medicine, 11 have faculty appointments, and 8 are PIs of independent research labs in Europe, North America, and China. Dr. Pu is also the contact PI of the Boston Children’s Hospital Department of Cardiology T32 training grant and the Director of Basic and Translational Cardiovascular Research for the Department of Cardiology at Boston Children’s Hospital.

Jean Zhao, PhDDana-Farber Cancer Institute, Harvard Medical School?
Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. Her laboratory has pioneered a new front for understanding signal transduction by integrating mouse genetics, chemical biology and immunology in the field of translational cancer research. Her productive and insightful work on deciphering the role of PI3-kinase isoforms and the cyclin D1-CDK4/6 pathway in cancer not only addresses important basic science questions, but also has had a?significant clinical impact. By providing a mechanistic understanding of the synergies gained for targeting PI3K isoforms and CDK4/6 in combination with immune checkpoint blockade in cancer, her lab has guided the design of current clinical trials of integrating immunotherapy and targeted therapy both here at DFCI and internationally.?
Dr. Jean Zhao is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Zhao has been widely recognized for her innovation and excellence in the field. After obtaining her Ph.D. degree with honors from Tufts University School of Medicine in Boston, Dr. Zhao completed her postdoctoral training in the laboratory of Dr. Thomas M. Roberts at DFCI. Dr. Zhao began her independent research at HMS and DFCI in 2006. Her honors and awards include the Career Development Awards from NIH/NCI, the V Scholar Award, the Starr Foundation Award and, recently, the Outstanding Investigator Award from NIH/NCI. Dr. Zhao serves as a member on multiple scientific boards and committees, including the Executive Committee for Research and the Committee for Women Faculty at DFCI, the Steering Committee of Breast Cancer at DF/Harvard Cancer Center and the Advisory Council of the National Brain Tumor Society.

Wenyi Wei, PhDBeth Israel Deaconess Medical Center, Harvard Medical School
The major focus of research in Dr. Wei’s laboratory is aimed at understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. More specifically, Dr. Wei is interested in elucidating the underlying mechanisms that define the oscillation of APC and SCF activity in different cell cycle phases. Currently, he is pursuing the underlying mechanisms that timely regulate APC/Cdh1 activity in different cell cycle phases. Additionally, Dr. Wei is also interested in understanding whether other layers of crosstalk between the APC and SCF complex exist. Furthermore, Dr. Wei would like to identify novel downstream targets for both APC and SCF complexes, which will help pinpoint their functions in both cell cycle control and tumor formation. To this end, Dr. Wei has developed biochemical purification approaches that would allow him to identify novel downstream targets for APC/Cdh1 and SCF/Fbw7 complexes. In addition, he is also interested in defining the tumor suppressor function of Cdh1 utilizing conditional Cdh1 knockout mice. To achieve these goals, Dr. Wei’s lab will use multidisciplinary approaches including biochemical and genetic analysis.?
Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards?Dr. Wei received his Ph.D. training in the Department of Molecular Biology, Cell Biology & Biochemistry (MCB) at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI and Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center and Department of Pathology at Harvard Medical School.?


Nathanael Gray, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Nathanael Gray’s research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. Dr. Gray has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Amongst the additional notable achievements of Dr. Gray’s research laboratory are: development of the first T790M selective EGFR inhibitors, ATP-competitive mTor inhibitor, Torin1, and its use to discover that rapamycin is an incomplete inhibitor of mTOR; development of the first inhibitors of ERK5 (BMK1), CDK7 and CDK12.?
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. In 2006, Dr. Gray returned to academia and accepted a faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School in Boston. Dr. Gray’s scientific contributions have been recognized through numerous awards including the Career Award of the National Science Foundation in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011.

Jiahuai Wang, PhDDana-Farber Cancer Institute, Harvard Medical School
Dr. Wang’s lab has been focusing on structures of cell surface receptors that play critical roles in the?immune system and nervous system. In collaboration with colleagues within Dana-Farber and Harvard Medical School, the Wang lab has worked out structures of a number of key immune molecules, including T cell receptors, MHC molecules, co-receptors and their interacting complexes. His group has also determined structures of many cell adhesion molecules, such as CD2, CD58, Cadherin, ICAM family members and the complexes with their interacting partners. More recently he begins to turn his interests into neuronal receptors. Most recently in collaboration with a group at EMBL, Hamburg, Dr. Wang has determined the?structure of netrin-1 in complex with DCC, uncovering the molecular mechanism of netrin-1 bi-functionality, a long-standing puzzle in the?neuroscience field.
Dr. Jiahuai Wang obtained his B.A from the University of Science and Technology of China in 1963 and an equivalent Ph.D. from the Beijing Biophysics Institute, Chinese Academy of Sciences in 1979. He had worked in Biophysics Institute in the period of 1963-1979. During 1979-1982, he was a visiting scholar at University of Wisconsin at Madison and at Harvard University, the Department of Biochemistry and Molecular Biology. In 1982-1988 he was back in Beijing Biophysics Institute, promoted to Associate Professor and later Professor. He served as director of Protein Crystallography Department there in 1987-1988. He was appointed as a member of National 863 Committee of Biotechnology of China in 1986-1990. He came to the United States again late in 1988 working at Harvard Medical School, the same department till 1996 before moving to Dana-Farber Cancer Institute as a Principal Investigator. In 2001, he was promoted as an Associate Professor of Pediatrics and Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Xiaoliang Sunney Xie, PhDDepartment of Chemistry and Chemical Biology, Harvard University
Dr. Xiaoliang Sunney Xie received a B.S. from Peking University in 1984, and his Ph.D. from the University of California at San Diego in 1990, followed by a short postdoctoral experience at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he later became a Chief Scientist. In 1999, he was appointed Professor of Chemistry at Harvard University. He was the first full professor at Harvard University from the People's Republic of China since China's reform in 1978. He is currently the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard, and the Director of Beijing Advanced Innovation Center for Genomics at Peking University.
Xie is among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s. He has made major contributions to the emergence of the field of single-molecule biophysical chemistry and its application to biology. His team also pioneered the development of coherent Raman scattering microscopy and single cell whole genome sequencing.
His honors include the Albany Prize in Medicine and Biomedical Research, the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, the National Institute of Health Director’s Pioneer Award, the Sackler Prize for Physical Sciences and the American Chemical Society’s Peter Debye Award. Xie is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from China, Germany and Israel.?


2018 Harvard Chinese Life Sciences YONGJIN Distinguished Research Award Awardees

Harvard Chinese Life Sciences YONGJIN Distinguished Research Award?is sponsored by Yongjin Group, which is to reward Chinese scientists whose research and discoveries were published or accepted for publication in 2017 & 2018 and well recognized by the scientific community. After tons of applications and some seriously stiff competition, we're super excited to announce that the following twelve researchers are awarded 2018 Harvard Chinese Life Sciences YONGJIN Distinguished Research Award!?
They will be awarded at the Harvard Chinese Life Science Annual Research Symposium on May 5, 2018, the symposium will take place at the Folkman Auditorium, Enders Building, Boston Children’s Hospital, 320 Longwood Ave, Boston, MA 02115.


Diamond Sponsors:


Gold Sponsors:



Registration:

Registration is FREE for students, scholars, and postdocs (with?.edu?email) !?
Registration is REQUIRED to attend this event.
Refreshment and lunch will be provided with RSVP !?
Please register by recognizing the QR code, or click?

Organizer:

哈佛医学院华人专家学者联合会
Website:?http://www.hms-cssa.org
微信公众号:?hmscssa